RT Conference Proceedings
T1 Concordance of baseline RAS mutational status (ms) between tissue and cell-free DNA (cfDNA) and association with overall response rate (ORR) in first-line (1L) metastatic colorectal cancer (mCRC) patients (pts): PERSEIDA study (cohort 2) (NCT02792478)
A1 Valladares-Ayerbes, M.
A1 Safont, M. J.
A1 Gonzalez-Flores, E.
A1 Garcia-Alfonso, P.
A1 Aranda Aguilar, E.
A1 Lopez-Munoz, A. M.
A1 Cirera-Nogueras, L.
A1 Falco-Ferrer, E.
A1 Rodriguez-Salas, N
A1 Aparicio, J.
A1 Llanos, M.
A1 Castillo-Trujillo, O.A.
A1 Pimentel-Caceres, P.
A1 Cruz-Hernandez, J. J.
A1 Salgado-Fernandez. M., 
A1 Salud-Salvia, A.
A1 Garcia-Carbonero, R.
A1 Massuti-Sureda, B.
A1 Vicente-Conesa, M. A.
A1 Lloansi-Vila, A.
K1 Humans
K1 Cell-Free Nucleic Acids
K1 Standard of Care
AB Tumor - tissue biopsy is the standard of care (SOC) to assess  RAS  & BRAF ms in mCRC pts. However, the analysis of circulating cfDNA has the advantage of evidencing genetic  tumor heterogeneity. We explored the occurrence of KRAS, NRAS and BRAF sequence variants (sv) using cfDNA in 1L SOC  RAS  wt mCRC pts. The concordance of  RAS  ms between tissue and cfDNA , and the association of cfDNA   RAS  ms and ORR were also explored.
PB Elsevier
SN 0923-7534
YR 2021
FD 2021-09-21
LK https://hdl.handle.net/10668/25694
UL https://hdl.handle.net/10668/25694
LA en
NO Valladares-Ayerbes, M., Safont, M. J., Gonzalez-Flores, E., Garcia-Alfonso, P., Aranda Aguilar, E., Lopez-Munoz, A. M., et al. Concordance of baseline RAS mutational status (ms) between tissue and cell-free DNA (cfDNA) and association with overall response rate (ORR) in first-line (1L) metastatic colorectal cancer (mCRC) patients (pts): PERSEIDA study (cohort 2) (NCT02792478). Ann. oncol. 2021-09-21; (32); S560
DS RISalud
RD Apr 17, 2025